The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Memantine in treatment of Alzheimer’s disease: 20 years of clinical use

Authors:

Gavrilova S.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6‑2): 10‑18

DOI: 10.17116/jnevro20161166210-18

Read: 7058 times

Download PDF (RU)
Contact the author
Table of contents

MEMANTINE IN TREATMENT OF ALZHEIMER’S DISEASE: 20 YEARS OF CLINICAL USE
MEMANTINE IN TREATMENT OF ALZHEIMER’S DISEASE: 20 YEARS OF CLINICAL USE

To cite this article:

Gavrilova SI. Memantine in treatment of Alzheimer’s disease: 20 years of clinical use. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6‑2):10‑18. (In Russ.)
https://doi.org/10.17116/jnevro20161166210-18

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Unre­solved problem: Chemotherapy-Induced Peri­pheral Neuropathy. P.A. Herzen Journal of Onco­logy. 2024;(5):76-81
Quality asse­ssment of health care deli­very to patients with sexually transmitted infe­ctions in dermatovenereological institutions of Moscow acco­rding to medi­cal reco­rds analysis. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):503-509
Psoriasis in pregnant women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):517-524
Tube­rculous otitis media in an adolescent. Clinical case. Russian Bulletin of Otorhinolaryngology. 2024;(5):63-66
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Comparative analysis of the resu­lts of treatment of gastric polyps by methods of loop electroexcision, laser and endo­scopic poly­pectomy with aspi­ration capture. Endo­scopic Surgery. 2024;(6):24-30
Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):709-712
Acti­vation of endo­genous mechanisms of sano­genesis in cognitive impairment in cere­bral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):7-13
Cognitive impairment in bili­nguals with neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):26-29
Abstract:

Alzheimer’s disease (AD) is a common neurodegenerative disease with progressive course which leads to severe dementia. The author considers the issues of pathogenesis and diagnosis of AD. The efficacy and safety of memantine are analyzed in depth. Recommendations for clinicians on the use of memantine in patients with AD are presented.

Keywords:

dementia
Alzheimer’s disease
memantine
treatment

Authors:

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Close metadata

References:

  1. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B.The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155-162.
  2. Double A. Pharmacology and Therapeutics. 1999;81:3:163-221.
  3. Greenamyre JT, Young AB, Penney JB. Quantative autoradiographic distribution of L-[3H] glutamate-binding sites in rat central nervous system. Neurosci. 1984;4:2133-2144.
  4. Braak H, Braak E. Pathology of Alzheimer’s disease. In: Calne D.B. (ed.) Neurodegenerative disease. Philadelphia: Saunders; 1994;585-613.
  5. Wenk GL, Danysz W, Mobley SL. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res. 1994;655:7-11.
  6. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J PharmacEnv Tox Pharmacol. 1995;293:267-270.
  7. Wenk GL, Hauss-Wegrzyniak B, Baker LM. Potential therapies for a novel animal model of Alzheimer’s disease - chronic neuroinflammation of transgenic rats that overexpress human 3-amyloid. Nerobiol Aging. 1998;19:129.
  8. Miguel Hidalgo JJ, Alvarez XA, Quack G, Cacabelos R. Protection by memantine against Ab (1-40)-induced neurodegeneration in CA1 subfield. NeurobiolAging. 1998;19:542.
  9. Gavrilova S.I., Kalyn Ya.B., Kolykhalov I.V., Mikhailova N.M., Roshchina I.F., Selezneva N.D., Zharikov G.A., Radzivill G.G. Akatinol memantin - modulyator glutamatergicheskoi sistemy v lechenii dementsii al'tsgeimerovskogo tipa. Sotsial'n i klinich psikhiatr. 1995;2:78-89.
  10. Ditzer K. Efficacy and tolerability of memantine in patients with dementia syndrome. Drug Res. 1991;41:773-780.
  11. Gortelmeyer R, Erbler H. Memantine in treatment of mild to moderate dementia syndrome. Drug Res. 1992;904-913.
  12. Gortelmeyer R, Pantev M, Parsons CG, Quack G. The treatment of dementia syndrome with Akatinol Memantine, a modulator of the glutamatergic system. In: Wild K. (Hrsq.): Spektrum der Neurorehabilitation; 1993;50-56.
  13. Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychologie und - psychiatric. 1993;6:103-117.
  14. Gottfries CG, Bråne G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch Gerontol Geriatr. 1982;1:311-330.
  15. McKhann G, Drachman D, Spano F et al. Clinical diagnosis of Alzheimer`s disease: report of the NINCDS-ADRDA Work Group. Neurology. 1984;146:939-944.
  16. Luriya A.R. Osnovy neiropsikhologii. M.: Izd-vo MGU; 1973.
  17. Roshchina I.F., Gavrilova S.I., Zharikov G.A. i dr. Otsenka effektivnosti terapii akatinolom memantinom bol'nykh s bolezn'yu Al'tsgeimera po rezul'tatam neiropsikhologicheskogo testirovaniya. Psikhiatriya i farmakoterapiya. 2002;6:34-40.
  18. ISS Integrated Summary of Safety for Memantine (Merz + Co.). 2000.
  19. Winblad B, Poritis N, Mobiuss H-J. Clinical improvment in a placebo-controlled trial with memantine in care-dependent patients with severe dementia. In: Ingrad K., Swaab D.F., Winblad B., Wisnievski H.M. (ed.). Alzheimer’s Disease and Related Disorders. Etiology, Pathogenesis and Therapeutics. John Wiley and SonsLtd. 1999;633-639.
  20. Gavrilova S.I., Kalyn Ya.B., Kolykhalov I.V. i dr. Novye vozmozhnosti kholinergicheskoi terapii bolezni Al'tsgeimera. Psikhiatriya. 2005;2:39-47.
  21. Gavrilova S.I., Kalyn Ya.B., Selezneva N.D. i dr. Glutamatergicheskaya terapiya bolezni Al'tsgeimera na stadii umerenno-tyazheloi i tyazheloi dementsii: rezul'taty 26 nedel'nogo issledovaniya effektivnosti i bezopasnosti preparata akatinol memantin. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 2005;2:72-76.
  22. Gautheir S, Wirth Y, Möbius HJ. Effects of Memantine in Behavioural Symptoms in Alzheimer’s Disease Patients: An Analysis of the Neuropsychiatric Inventory (NPI) Data of Two Randomized, Controlled Studies. Int J GeriatrPsychiatry. 2005;20:1-6.
  23. Bakchine S. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, doubleblind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97-107.
  24. Winblad B, Jones RW, Wirth Y et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomized clinical trials. Dement GeriatrCogn Disord. 2007;24(1):20-27.
  25. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Metaanalysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement. 2007;3(1):7-17. Meta-Analysis of the Efficacy of Memantine in AD 581.
  26. IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Memantine Alzheimer bei Demenz. Abschlussbericht. IQWiG-Berichte-Jahr. 2009;59.
  27. Lundbeck. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of memantine in patients with dementia of the Alzheimer’s type. http://www.lundbecktrialscom.com/Data/PDFs/10116_Final_11Oct2006_CTRSpdf. 2006.
  28. PenTAG. Peninsula Technology Assessment Group (PenTAG), University of Exeter. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease: a systematic review and economic model. 2010. https:// guidance.nice.org.uk/TA/WaveR111/1//AssessmentReport.
  29. Rive B, Gauthier S, Costello S et al. Synthesis and Comparison of Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s disease. CNS Drugs. 2013;27:573-582.
  30. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333-1341.
  31. van Dyck C. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-143.
  32. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-715.
  33. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.
  34. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, doubleblind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-89.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.